Latest period
$976M
YoY change
+4.8%
5Y CAGR
+4.9%
Peak year (FY2025)
$955M
Latest annual
$955M
Stock-Based Compensation history chart for AbbVie (ABBV) from 2016 to 2025
Latest: $955M
Stock-Based Compensation growth chart for AbbVie (ABBV) from 2016 to 2025
Latest: +4.8%
Stock-Based Compensation history table for AbbVie (ABBV) from 2009 to 2025
| FY2025 | $955M | +4.8% | +$44M | ||
| FY2024 | $911M | +22.0% | +$164M | ||
| FY2023 | $747M | +11.3% | +$76M | ||
| FY2022 | $671M | -3.0% | -$21M | ||
| FY2021 | $692M | -8.1% | -$61M | ||
| FY2020 | $753M | +75.1% | +$323M | ||
| FY2019 | $430M | +2.1% | +$9M | ||
| FY2018 | $421M | +15.3% | +$56M | ||
| FY2017 | $365M | +3.4% | +$12M | ||
| FY2016 | $353M | +25.2% | +$71M | ||
| FY2015 | $282M | +17.0% | +$41M | ||
| FY2014 | $241M | +13.7% | +$29M | ||
| FY2013 | $212M | +13.4% | +$25M | ||
| FY2012 | $187M | +14.7% | +$24M | ||
| FY2011 | $163M | -2.4% | -$4.02M | ||
| FY2010 | $167M | +6.6% | +$10.3M | ||
| FY2009 | $157M | — | — |
- FY2025$955M+4.8%
- FY2024$911M+22.0%
- FY2023$747M+11.3%
- FY2022$671M-3.0%
- FY2021$692M-8.1%
- FY2020$753M+75.1%
- FY2019$430M+2.1%
- FY2018$421M+15.3%
- FY2017$365M+3.4%
- FY2016$353M+25.2%
- FY2015$282M+17.0%
- FY2014$241M+13.7%
- FY2013$212M+13.4%
- FY2012$187M+14.7%
- FY2011$163M-2.4%
- FY2010$167M+6.6%
- FY2009$157M—
Stock-Based Compensation values are taken from AbbVie's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at AbbVie (ABBV)
Stock-Based Compensation for AbbVie (ABBV): headline value $976M · YoY +4.8%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual stock-based compensation for AbbVie (ABBV) came in at $955M – edged up 4.8% year-over-year.
Over 2020–2025 (5 years), AbbVie stock-based compensation expanded at a +4.9% compound annual rate, with mixed annual results across the window.
Across the available history, stock-based compensation reached its high of $955M in 2025 and its low of $157M in 2009.
AbbVie Stock-Based Compensation by Year
AbbVie Stock-Based Compensation 2025: $955M
2025's stock-based compensation for AbbVie came in at $955M, edged up 4.8% from 2024. This figure represents the highest annual value in the available history.
AbbVie Stock-Based Compensation 2024: $911M
AbbVie posted stock-based compensation of $911M in 2024, grew 22.0% from 2023.
AbbVie Stock-Based Compensation 2023: $747M
In 2023, AbbVie reported stock-based compensation of $747M, grew 11.3% from 2022.
AbbVie Stock-Based Compensation 2022: $671M
AbbVie stock-based compensation in 2022 was $671M, edged down 3.0% below 2021.
AbbVie Stock-Based Compensation 2021: $692M
AbbVie stock-based compensation in 2021 was $692M.
See more financial history for AbbVie (ABBV).
Sector peers by Stock-Based Compensation
Healthcare peers of AbbVie (ABBV), ranked by their latest stock-based compensation
| $1.35B | |
| $971M | |
| $626M | |
| $494M | |
| $310M | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $626M
- $494M
- $0.00
- $0.00
- $0.00
Frequently asked questions
AbbVie (ABBV) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.